rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cel-Sci Corporation

CVM · NYSE American

Health CareBiotechnologyNot moving yet

CVM stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 50 weeks. It is 15.8% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 50
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$1.7M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
38 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$924KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Geert R. KerstenChief Executive Officerbought100,000at $1.3825 Aug 2026filed 26 Aug 2026
Geert R. KerstenChief Executive Officerbought300,000at $1.2014 May 2026filed 18 May 2026
Geert R. KerstenChief Executive Officerbought100,000at $1.1913 May 2026filed 14 May 2026
Geert R. KerstenChief Executive Officerbought38,023at $5.2622 Jan 2026filed 26 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders38+2 on the quarter
New · exited9 · 7
Reported value$2.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026572,460$595K+536,570+1495.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026543,079$565K+299,434+122.9%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026198,500$206K+198,500
MAI Capital Managementadded · filed 14 Aug 2026108,280$113K+17,000+18.6%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202688,200$92K+2,889+3.4%
COMMONWEALTH EQUITY SERVICES, LLCadded · filed 29 Jul 202651,434$53K+33,812+191.9%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202649,036$51K00.0%
BlackRock, Inc.unchanged · filed 7 Aug 202643,261$45K00.0%
BANK OF AMERICA CORPreduced · filed 14 Aug 202640,916$43K-81−0.2%
JANE STREET GROUP, LLCnew · filed 14 Aug 202636,458$38K+36,458
30 Jun 2025 – 30 Jun 2026
273338Jun 25Sep 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Eyal Talor Company insiderChief Scientific Officer · last 30 Sep 20261 · 12
Geert R. Kersten Company insiderChief Executive Officer · last 30 Sep 202629 · 0
Patricia B. Prichep Company insiderChief Financial Officer · last 30 Sep 20264 · 0
Bruno Jean-Marie Baillavoine Company insiderDirector · last 14 Aug 20263 · 0
John Cipriano Company insiderSenior Vice President · last 14 Aug 20261 · 5
Robert Eugene Watson Company insiderDirector · last 14 Aug 20265 · 0
Gail K. Naughton Company insiderDirector · last 8 Aug 20230 · 0
Peter R. Young Company insiderDirector · last 8 Aug 202313 · 0
Daniel H. Zimmerman Company insiderSenior Vice President · last 30 Sep 20222 · 2
Alexander G. Esterhazy Company insiderDirector · last 12 Jun 20170 · 0
Clara Maximilian De Company insiderOther · last 31 Aug 20160 · 21
C. Richard Kinsolving Company insiderDirector · last 6 Aug 20140 · 1

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 30 Sep 2025-108%
Interest coverFY 2025 · to 30 Sep 2025-38.23×
Share count trendFY 2025 · to 19 Dec 20254.9%
Cash and equivalentsFY 2025 · to 30 Sep 2025$11.0M
Free cash flowFY 2025 · to 30 Sep 2025−$17.2M

Analyst forecasts

No analyst forecasts yet.